List of Excipients in Branded Drug DESLORATADINE

« Back to Dashboard

Generic Drugs Containing DESLORATADINE

Company	Ingredient	NDC	Excipient
AvKARE	desloratadine	42291-240	CELLULOSE, MICROCRYSTALLINE
AvKARE	desloratadine	42291-240	CROSCARMELLOSE SODIUM
AvKARE	desloratadine	42291-240	FD&C BLUE NO. 2

What are the Most Frequently-Used Excipients in DESLORATADINE?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	ANHYDROUS LACTOSE
1	ASPARTAME

Desloratadine Excipient Strategy, Patent Status, and Commercial Opportunities

Last updated: August 25, 2026

Desloratadine is a mature, genericized second-generation antihistamine with limited remaining U.S. patent barriers. The commercial opportunity is concentrated in differentiated dosage forms, pediatric delivery, sugar-free liquids, taste-masked products, orally disintegrating tablets, combination products, and regional OTC expansion. Excipient selection should prioritize rapid disintegration, low-dose content uniformity, palatability, moisture control, and broad regulatory acceptability.

What is the market status of desloratadine?

Desloratadine is the active metabolite of loratadine and selectively antagonizes peripheral histamine H1 receptors. It is marketed for allergic rhinitis and chronic idiopathic urticaria in tablets, orally disintegrating tablets, oral solutions or syrups, and combination products in some markets.

Attribute	Desloratadine
Active ingredient	Desloratadine
Common strength	5 mg
Pediatric strengths	Commonly 0.5 mg/mL oral solution or equivalent
Original U.S. brand	Clarinex
Original sponsor	Schering-Plough, later part of Merck
U.S. NDA	NDA 021165
FDA approval	2001
Drug class	Second-generation H1 antihistamine
U.S. status	Generic competition established
Biosimilar exposure	None; desloratadine is a small molecule
Principal dosage forms	Tablet, orally disintegrating tablet, oral solution
Main commercial markets	Allergic rhinitis, urticaria, pediatric allergy care, regional OTC markets

The reference product label lists tablets containing 5 mg desloratadine and inactive ingredients including lactose monohydrate, microcrystalline cellulose, pregelatinized starch, talc, titanium dioxide, and coating materials. The oral solution uses a liquid system based on water, sweeteners, polyols, buffers, preservatives, chelators, and flavoring agents.[1]

What excipients are used in desloratadine products?

Immediate-release tablets

A conventional 5 mg desloratadine tablet has a relatively high active-to-tablet ratio compared with many low-dose drugs. The formulation challenge is less about achieving a high drug load and more about maintaining content uniformity, rapid dissolution, tablet robustness, and acceptable coating performance.

A representative tablet architecture includes:

Formulation function	Typical excipient options	Commercial purpose
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Controls tablet size and compression behavior
Binder	Pregelatinized starch, povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Coating polymer	Hypromellose, polyvinyl alcohol	Protects tablet and improves appearance
Opacifier or pigment	Titanium dioxide, iron oxides	Supports product identification and light protection
Anti-tacking agent	Talc	Improves coating processability

For a generic immediate-release product, lactose-microcrystalline cellulose systems are familiar to regulators and manufacturers. Mannitol-based systems can support a premium positioning, particularly where a low-sugar or better mouthfeel profile is desired. Dibasic calcium phosphate can improve flow and hardness but may increase formulation density and influence disintegration.

What excipient strategy is best for a desloratadine orally disintegrating tablet?

An orally disintegrating tablet, or ODT, is the strongest dosage-form opportunity for product differentiation. Desloratadine is administered at a low dose, making it suitable for direct compression or specialized ODT manufacturing.

Preferred ODT excipient platform

A practical ODT formulation may use:

• Mannitol as the principal filler and cooling-mouthfeel agent
• Crospovidone or croscarmellose sodium as the disintegrant
• Microcrystalline cellulose for compactibility
• Low levels of colloidal silicon dioxide for flow
• Magnesium stearate or sodium stearyl fumarate as lubricant
• Aspartame, sucralose, or a high-intensity sweetener for taste correction
• Flavoring agents such as cherry, berry, or mint
• Citric acid or malic acid to improve flavor balance
• A moisture-barrier blister as the primary package

The target is disintegration in approximately 30 seconds or less under the applicable pharmacopoeial method, without excessive friability or unacceptable mouth residue. Rapid disintegration does not necessarily create a faster clinical onset because systemic exposure remains dependent on absorption and pharmacokinetics. The commercial value is convenience, water-free administration, and pediatric or travel use.

Which excipients create the main ODT risks?

Risk	Likely cause	Control strategy
Slow disintegration	Excess binder, over-lubrication, high compression force	Reduce binder and lubricant; optimize compression
Chipping or friability	Insufficient binder or weak compactibility	Use microcrystalline cellulose or copovidone
Bitter or medicinal taste	Drug exposure during oral disintegration	Use flavor-sweetener combinations and taste masking
Moisture sensitivity	Hygroscopic excipients or porous tablet structure	Use alu-alu blister and low-moisture processing
Sticking and picking	Low melting or poorly lubricated blend	Optimize lubricant and tooling
Variable dose uniformity	Low active concentration and segregation	Use ordered mixing, granulation, or geometric dilution
Excessive mouth residue	High insoluble excipient load	Prefer soluble mannitol and controlled disintegrant levels

A co-processed mannitol-cellulose excipient may reduce development time by improving flow and compressibility. It can also reduce the number of formulation components, although the product must still demonstrate acceptable content uniformity and dissolution.

What excipients are best for desloratadine oral solution?

The oral solution is commercially important because allergy treatment includes young children who cannot reliably swallow tablets. The primary formulation priorities are dose accuracy, palatability, preservative efficacy, chemical stability, microbial control, and compatibility with dosing syringes.

Liquid formulation options

Function	Conventional choices	Strategic considerations
Vehicle	Purified water	Standard regulatory platform
Sweetener	Sucrose, sorbitol, sucralose, sodium saccharin	Sucrose improves taste but creates sugar-related restrictions
Humectant	Propylene glycol, glycerin, sorbitol	Controls mouthfeel and solubilization
Buffer	Citric acid/sodium citrate, phosphate buffer	Controls pH and stability
Preservative	Sodium benzoate, potassium sorbate	Requires preservative efficacy testing
Chelator	Disodium edetate	Can improve stability by binding trace metals
Flavor	Berry, cherry, grape, mixed fruit	Strong effect on pediatric acceptance
Coloring	Certified dyes or color-free system	Color-free products reduce sensitivity concerns

A sugar-free oral solution using sorbitol, glycerin, and sucralose can address diabetic consumers, dental-health concerns, and institutional formularies. Sorbitol levels must be managed because excessive intake can cause gastrointestinal discomfort. A sucrose-free and alcohol-free product broadens pediatric and international market access.

The formulation should be assessed for precipitation, pH drift, preservative performance, flavor stability, and dose uniformity over the proposed shelf life. The dosing device is part of the commercial product. A calibrated oral syringe generally provides better pediatric dose accuracy than a household teaspoon.

What formulation patents protect desloratadine products?

The original U.S. desloratadine estate was directed primarily to the active compound and related pharmaceutical use. The historic Clarinex product also relied on dosage-form and formulation disclosures, but the principal commercial barrier has expired.

Patent or regulatory right	Relevance	Current commercial effect
U.S. Patent No. 5,595,997	Historically associated with desloratadine protection	Expired
Original compound and use claims	Covered the active ingredient and allergy indications	Expired in the United States
Pediatric exclusivity associated with the reference product	Extended certain regulatory protections after pediatric studies	Expired
Product-specific formulation claims	Potentially relevant to particular ODT, liquid, or release systems	Must be assessed by product and jurisdiction
ANDA certification rights	Enabled generic entry after patent barriers fell	Active pathway for new applicants

The key distinction is between expired compound patents and any later patents directed to a specific formulation, manufacturing process, combination, or delivery system. A generic applicant cannot assume that the absence of an active compound patent eliminates every possible formulation issue. The relevant claims must be screened for claim scope, expiration, terminal disclaimers, prosecution history, and geographic coverage.

What is the Orange Book status of desloratadine?

The U.S. Orange Book historically listed Clarinex and associated patent information. The original patents protecting desloratadine have expired, and generic desloratadine products have entered through the abbreviated new drug application pathway.[2]

Orange Book issue	Desloratadine position
Reference listed drug	Clarinex
ANDA pathway	Available
Active compound exclusivity	Expired
Historical Paragraph IV relevance	Primarily associated with earlier generic entry
Current generic barrier	Formulation, regulatory, manufacturing, or commercial rather than basic compound patent protection
Therapeutic equivalence	Product-specific and dosage-form-specific

Paragraph IV litigation was commercially relevant when generic applicants challenged the remaining Clarinex patents. That litigation period has passed for the core U.S. market. New applicants should focus on whether their product differs in inactive ingredients, dosage form, labeling, strength, or device sufficiently to create a distinct regulatory or commercial profile.

When did desloratadine lose exclusivity?

Desloratadine lost U.S. compound-level exclusivity in the mid-2010s. Generic competition is now established. The precise date depended on the patent term, pediatric extension, regulatory exclusivity, and the dosage form at issue.

The exclusivity timeline is summarized below:

Period	Event
1990s	Desloratadine compound and related rights developed
2001	FDA approved Clarinex
Early 2000s	Reference product expanded into pediatric and ODT presentations
2010s	Core U.S. patent and pediatric protection expired
2010s onward	Generic tablets and liquid products became commercially available
Current market	Competition based on price, supply reliability, dosage form, taste, and distribution

International exclusivity dates vary because patent filings, supplementary protection certificates, national approvals, and local regulatory exclusivity are jurisdiction-specific.

What generic entry risks exist for desloratadine?

Generic entry risk is high for standard 5 mg tablets and established oral solutions. A new entrant faces limited patent risk but significant price and channel competition.

Standard tablet risk

The standard tablet is the most commoditized segment. A successful product generally requires:

• Low manufacturing cost
• Reliable API supply
• Strong content uniformity
• Rapid dissolution
• High manufacturing yield
• Competitive wholesaler pricing
• Broad pharmacy and tender access

A generic tablet with no dosage-form differentiation is vulnerable to price erosion and substitution.

ODT risk

ODTs have lower direct price competition than conventional tablets but higher technical risk. The main barriers are taste masking, friability, moisture protection, and package cost. A product that combines a low-cost tablet with a robust unit-dose blister can obtain better pharmacy and consumer positioning than a conventional bottle product.

Oral solution risk

The oral solution segment has more room for differentiation. Commercial advantages can come from:

• Preservative-free or reduced-preservative positioning
• Sugar-free formulation
• Alcohol-free formulation
• Clear or color-free presentation
• Improved flavor
• Dosing syringe included in the package
• Smaller pediatric bottle sizes
• Compatibility with retail and hospital dispensing systems

The primary risks are microbial contamination, preservative failure, taste rejection, and supply-chain complexity associated with liquids.

What commercial opportunities exist for desloratadine excipient innovation?

Pediatric allergy products

Pediatric oral solutions and chewable or ODT products are the clearest opportunities. Formulation development should prioritize:

• Accurate low-volume dosing
• Low sugar or sugar-free composition
• No ethanol
• Taste masking
• Child-resistant but caregiver-friendly packaging
• Stability across temperature excursions
• Syringe-based dosing

A product that reduces dosing friction can compete even when the active ingredient is fully generic.

Premium ODT products

A fast-dissolving tablet with improved taste and moisture-resistant packaging can target adults who avoid water-based dosing, travelers, and patients with swallowing difficulties. The product can be positioned through convenience rather than clinical superiority.

Combination products

Desloratadine may be combined regionally with pseudoephedrine or other decongestant actives. Combination products can command higher net prices but introduce additional regulatory, labeling, safety, and patent-screening requirements. The formulation must manage different dose levels, dissolution profiles, and stability requirements.

OTC expansion

Desloratadine is available without prescription in several markets. OTC opportunities depend on local monograph rules, labeling requirements, switch status, and pharmacy distribution. A consumer product needs strong palatability, clear age-based dosing, package differentiation, and high retail availability.

International licensing and contract manufacturing

The most realistic licensing opportunities involve:

• Regional marketing rights
• Local registration and distribution
• Pediatric liquid supply
• ODT technology
• Taste-masking platforms
• Low-cost manufacturing
• Private-label pharmacy products

No active U.S. compound patent is required for these opportunities. Value is more likely to come from regulatory registrations, manufacturing capacity, brand access, and differentiated presentation.

How strong is the desloratadine patent estate?

The core U.S. patent estate is weak from a current freedom-to-operate perspective because the principal compound protection has expired. The estate remains relevant historically and must still be screened in jurisdictions where patent terms or local rights differ.

Estate component	Strength in current U.S. market	Business implication
Core compound claims	Low	Does not block generic entry
Original therapeutic-use claims	Low	Expired or commercially ineffective
Standard tablet claims	Low to moderate	Usually not a meaningful barrier
ODT claims	Product-specific	May matter for a narrowly claimed technology
Liquid formulation claims	Product-specific	Screen excipient combinations and stability claims
Manufacturing claims	Variable	Can affect API or dosage-form sourcing
Device and packaging claims	Variable	Relevant to differentiated products
International rights	Country-specific	Requires national patent review

The commercial strength of a new product will depend more on formulation execution than on the legacy desloratadine patent portfolio.

How does desloratadine compare with competing antihistamines?

Drug	Common dosage forms	Generic maturity	Main differentiation opportunity
Desloratadine	Tablet, ODT, oral solution	High	Pediatric liquid, taste, ODT, OTC access
Loratadine	Tablet, chewable, syrup, ODT	High	Price, broad retail presence
Cetirizine	Tablet, chewable, solution	High	Rapid consumer recognition and pediatric use
Levocetirizine	Tablet, solution	High	Prescription and OTC positioning
Fexofenadine	Tablet, suspension	High	Non-sedating positioning and larger dose formats

Desloratadine competes in a crowded antihistamine market. Its commercial advantage is not exclusivity. It is the ability to offer a differentiated, well-tolerated, convenient product with reliable supply and competitive pricing.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are modest for conventional tablets but higher for liquids and ODTs.

API and supply chain

Desloratadine API sourcing should be evaluated for:

• DMF or equivalent regulatory support
• Impurity profile
• Residual solvents
• Particle-size distribution
• Polymorphic form
• Batch-to-batch assay variability
• Nitrosamine and elemental impurity controls
• Dual-source availability

Particle-size control can affect blend uniformity and dissolution. Low-dose formulations require validated sampling and blending controls even when the active is chemically stable.

Formulation and process IP

The most relevant new IP opportunities include:

• Taste-masked desloratadine particles
• Porous ODT matrices
• Co-processed excipient systems
• Stabilized aqueous solutions
• Preservative-reduced liquids
• Unit-dose delivery systems
• Fixed-dose allergy combinations
• Manufacturing processes that improve yield or reduce compression defects

A defensible formulation patent should claim a measurable technical result, such as dissolution, stability, taste-masking performance, disintegration time, or impurity control. Broad claims covering conventional excipients alone are less likely to provide durable commercial protection.

What is the revenue exposure from desloratadine?

Revenue exposure for the original branded product has declined substantially because the active ingredient is genericized. For manufacturers, the opportunity is usually a portfolio contribution rather than a standalone blockbuster.

Product type	Revenue profile	Margin outlook
Conventional generic tablet	High volume, low price	Low
ODT	Moderate volume, premium positioning	Moderate
Pediatric oral solution	Moderate volume, differentiated	Moderate to high
Branded OTC product	Retail-dependent	Variable
Combination product	Higher unit value	Moderate, with added regulatory complexity
Regional licensed product	Market-specific	Variable
Private-label product	High channel dependence	Low to moderate

The best return on development investment is likely to come from a low-cost ODT, a differentiated pediatric liquid, or a combination of both across multiple markets.

Key Takeaways

• Desloratadine is a mature small-molecule antihistamine with established generic competition.
• Core U.S. compound and regulatory exclusivity protections have expired.
• Standard 5 mg tablets are highly commoditized and offer limited formulation-driven pricing power.
• ODTs provide the strongest opportunity for excipient-led differentiation.
• Pediatric oral solutions can compete through taste, sugar-free composition, dosing accuracy, and packaging.
• Mannitol, crospovidone, microcrystalline cellulose, taste-masking systems, and moisture-barrier packaging are central development tools.
• Liquid formulations require close control of pH, preservative efficacy, microbial quality, and chemical stability.
• New patent value is more likely to arise from specific formulation, process, device, or combination claims than from the desloratadine molecule.
• Biosimilar risk is irrelevant because desloratadine is a small molecule.
• Commercial success will depend on cost, supply reliability, dosage-form convenience, and regional regulatory execution.

FAQs

Can desloratadine be formulated without lactose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or a co-processed filler system. The replacement must be evaluated for hardness, disintegration, dissolution, content uniformity, and stability.

Is a sugar-free desloratadine syrup commercially viable?

Yes. A formulation based on sorbitol, glycerin, sucralose, or another high-intensity sweetener can support sugar-free positioning. Palatability, gastrointestinal tolerance, preservative efficacy, and dose accuracy determine commercial viability.

What is the best package for a desloratadine ODT?

A moisture-protective unit-dose blister, often based on an aluminum laminate, is generally preferable to a multidose bottle. Packaging selection should be based on moisture ingress, tablet friability, stability data, and cost.

Can desloratadine be used in a chewable tablet?

Yes. A chewable product requires stronger taste masking and a more robust flavor system than a swallowed tablet. Mannitol, xylitol, sweeteners, flavors, and coated or embedded drug particles may be used.

Does desloratadine have biosimilar competition?

No. Desloratadine is a chemically synthesized small molecule and competes through generic drug applications, not biosimilar applications.

References

1. U.S. Food and Drug Administration. (2023). Clarinex (desloratadine) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2001). Approval package for Clarinex (desloratadine), NDA 021165.
4. United States Patent and Trademark Office. (1999). U.S. Patent No. 5,595,997: Desloratadine.
5. U.S. Food and Drug Administration. (2024). Inactive ingredient database.
6. United States Pharmacopeia. (2024). General chapter <701> disintegration and related dosage-form standards.